Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:SLS News 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy (galinpepimut‑S, “GPS”) is in a Phase 3 AML trial (REGAL), which recently passed an interim safety review
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025, and the momentum accelerated in mid-October. On Friday Oct. 17, SLS closed at $2.14, up roughly 100% year-to-datefinbold.com. In fact, during that day’s session the stock touched a 52-week high of $2.27 (more than 3× its 52-week low of $0.77)marketbeat.com. Trading activity exploded as well – volume spiked to several times the usual level (over 6.7 million shares vs ~2.2M average) amid a flurry of speculative buying. Options
18 October 2025

Stock Market Today

Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

8 February 2026
Airbus shares rose 0.94% to 191.30 euros Friday as the company reported 19 aircraft deliveries in January, down from 25 a year earlier. Supply chain bottlenecks remain an issue, with executives at the Singapore Airshow calling delays “unacceptable.” Jefferies kept a Neutral rating and a 215-euro price target. Airbus will report full-year 2025 results on Feb. 19.
Banco Santander stock heads into Monday after Friday bounce as buyback and Webster deal loom

Banco Santander stock heads into Monday after Friday bounce as buyback and Webster deal loom

8 February 2026
Banco Santander shares closed up 1.85% at €10.66 in Madrid Friday after launching a €5.03 billion buyback and agreeing to acquire U.S. lender Webster Financial for $12.2 billion. Santander said its board will review the 2025 cash dividend proposal on Feb. 24. The bank also raised its UK motor finance redress provision to £461 million amid regulatory uncertainty.
Go toTop